John Overdeck’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-132,055
| Closed | -$2.87M | – | 3449 |
|
|
2017
Q2 | $2.87M | Sell |
132,055
-25,805
| -16% | -$468K | 0.01% | 1187 |
|
|
2017
Q1 | $2.21M | Buy |
+157,860
| New | +$2.59M | 0.01% | 1398 |
|
|
2016
Q4 | – | Sell |
-98,075
| Closed | -$1.62M | – | 3709 |
|
|
2016
Q3 | $1.62M | Buy |
98,075
+68,884
| +236% | +$1.02M | 0.01% | 1622 |
|
|
2016
Q2 | $392K | Sell |
29,191
-126,115
| -81% | -$1.84M | ﹤0.01% | 2410 |
|
|
2016
Q1 | $2.38M | Sell |
155,306
-21,732
| -12% | -$341K | 0.01% | 1085 |
|
|
2015
Q4 | $3.51M | Buy |
177,038
+142,867
| +418% | +$2.72M | 0.02% | 809 |
|
|
2015
Q3 | $595K | Sell |
34,171
-80,645
| -70% | -$1.64M | ﹤0.01% | 1459 |
|
|
2015
Q2 | $2.32M | Buy |
+114,816
| New | +$2.22M | 0.01% | 1105 |
|
|
2014
Q4 | – | Sell |
-60,116
| Closed | -$1.33M | – | 2488 |
|
|
2014
Q3 | $1.33M | Sell |
60,116
-77,693
| -56% | -$1.59M | 0.01% | 985 |
|
|
2014
Q2 | $2.77M | Buy |
137,809
+5,467
| +4% | +$92.6K | 0.01% | 912 |
|
|
2014
Q1 | $2.46M | Buy |
132,342
+105,640
| +396% | +$1.45M | 0.01% | 867 |
|
|
2013
Q4 | $269K | Buy |
+26,702
| New | +$323K | ﹤0.01% | 1923 |
|
|
2013
Q3 | – | Sell |
-10,003
| Closed | -$119K | – | 2264 |
|
|
2013
Q2 | $119K | Buy |
+10,003
| New | +$108K | ﹤0.01% | 1873 |
|
Other funds holding AMRI
John Overdeck's AMRI Position: Q3 2017 in Review
John Overdeck sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 132,055 shares — an estimated $2.87M sold.
John Overdeck first reported a position in AMRI in Q2 2013 and held it in 13 quarters. The position peaked at $3.51M in Q4 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- John Overdeck reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- John Overdeck sold 132,055 Albany Molecular Research Inc shares in Q3 2017, an estimated $2.87M.
- John Overdeck first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 13 quarters.
- John Overdeck's Albany Molecular Research Inc position peaked at $3.51M in Q4 2015.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Two Sigma Investments's 13F filing for Q3 2017, filed 14 Nov 2017.